Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG305

—

0c80af5d-325e-5dca-8c4d-a8f4a4cfca30

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • MYC_TARGETS_V2+0.294
  • MITOTIC_SPINDLE+0.230
  • PANCREAS_BETA_CELLS+0.221
  • UV_RESPONSE_DN+0.205
  • MYC_TARGETS_V1+0.181
  • APICAL_JUNCTION+0.145
  • DNA_REPAIR+0.131
  • INTERFERON_ALPHA_RESPONSE+0.127
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.121
  • KRAS_SIGNALING_DN+0.107

Top 10 suppressed

  • TNFA_SIGNALING_VIA_NFKB-0.330
  • OXIDATIVE_PHOSPHORYLATION-0.318
  • ANGIOGENESIS-0.271
  • INFLAMMATORY_RESPONSE-0.252
  • IL6_JAK_STAT3_SIGNALING-0.243
  • PEROXISOME-0.228
  • PI3K_AKT_MTOR_SIGNALING-0.222
  • APICAL_SURFACE-0.206
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.201
  • HEME_METABOLISM-0.199

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR4296090
lung-landscapes@6
—cohortMD10.724
2TCGA-CN-5367-01A-01R-1436-07
head-neck@1
——0.717
3f755bd47-f8ff-4847-9b8e-7d36b7b84155
colon-landscapes@1
——0.717
4SRR10842360
melanoma-umap@29
——0.715
5TCGA-GD-A3OS-01A-12R-A220-07
bladder-landscape@3
——0.712
6BS_VPBMDMQX
brain-umap@2
medulloblastoma—0.708
7MBCProject_1334_T1_RNA
breast-umap@18
—C0.707
8MNG357
mng-umap@100
——0.704
9TCGA-18-4083-01A-01R-1100-07
lung-landscapes@6
—cohortSQ20.683
10SRR975552
colon-landscapes@1
——0.680

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 18 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
MYC_TARGETS_V20.294Idelalisib— uncovered
MITOTIC_SPINDLE0.230Inavolisib— uncovered
PANCREAS_BETA_CELLS0.221Cobimetinib— uncovered
UV_RESPONSE_DN0.205Inavolisib— uncovered
MYC_TARGETS_V10.181Inavolisib— uncovered
APICAL_JUNCTION0.145Inavolisib— uncovered
DNA_REPAIR0.131Idelalisib— uncovered
INTERFERON_ALPHA_RESPONSE0.127Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.121Inavolisib— uncovered
KRAS_SIGNALING_DN0.107Remibrutinib— uncovered
SPERMATOGENESIS0.100Inavolisib— uncovered
E2F_TARGETS0.097Inavolisib— uncovered
HEDGEHOG_SIGNALING0.071Inavolisib— uncovered
MYOGENESIS0.067Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.067Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.062Idelalisib— uncovered
G2M_CHECKPOINT0.020Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.005Idelalisib— uncovered